In contrast to common obesity, where cardiovascular risk reduction drives intervention, the main rationale for treatment in MC4R -deficient patients shifts toward alleviating mechanical complications (e.g., sleep apnea, osteoarthritis), preventing diabetes (hyperinsulinemia is common despite relative euglycemia), and improving quality of life [30]
Separately, any patient who does not have insurance coverage for Wegovy or another GLP-1 can still buy Novo Nordisk's drug out-of-pocket for $499 at any of CVS' 9,000 pharmacies nationwide, the spokesperson added
If youre like me and committed to staying on track, no matter where life takes you, now is the time to take the next step
Guan Y, Niu H, Liu Z, Dang Y, Shen J, Zayed M, et al
Their simultaneous exit within a 12-month window fundamentally reshaped the competitive landscape
Baggiolini, M